A Study to Evaluate the Efficacy and Safety of ENX-102 in Participants With Social Anxiety Disorder

Ki vehet részt

• Male or female at birth, aged 18-70 years, inclusive, at screening Diagnosed with SAD according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), confirmed by a Mini-International Neuropsychiatric Interview (MINI) version 7.0.2
• LSAS total score of ≥70
• CGI-S score of ≥4

Ki nem vehet részt

• Used prohibited medication or prohibited herbal or other supplements within 5 half- lives or 21 days prior to Day 1 and unwillingness to refrain from their use for the duration of the trial
• Is unwilling/unable to abstain from alcohol, marijuana, THC, CBD, and/or any other psychoactive substances (except for nicotine or caffeine) for the duration of the trial, per Investigator judgment, and/or has a positive alcohol test or drug test at Screening or Day 1
• Clinically predominant psychiatric diagnosis other than SAD per the MINI
• Any past/lifetime or current diagnosis of a neurocognitive disorder or psychotic disorder, or any current diagnosis of posttraumatic stress disorder, obsessive compulsive disorder, or bipolar disorder
• Current or recent moderate or severe substance use disorder as assessed by the MINI
• Has significant progressive disorders or unstable medical conditions Unable to comply with the requirements of the study or, in the opinion of the Investigator or Sponsor, is unsuitable for the study
• Reports moderately severe to severe symptoms of depression
• Frequent use of benzodiazepines within 90 days of screening
• Recent suicidal ideation or behavior
• Clinically significant abnormal findings in safety assessments